Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD. The drugs discussed are listed below. The two interviews were combined into a single report.
Azasan (VRX), Cimzia, Cx601 (TIG), Entocort EC (PRGO), Entyvio (TKPYY), etrolizumab (RHHBF), filgotinib (GILD), GED 0301 (CELG), Humira (ABBV), Remicade (JNJ), Stelara (JNJ), Tysabri (BIIB), Xeljanz/Xeljanz XR (PFE).
As a special offer, we are pleased to make these two KOL interviews available free of charge to Biomedtracker clients.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.